アンジェス revised its consolidated revenue forecast for the 2026 fiscal year ending December downward to ¥1.0 billion, while the deficit narrowed. The company said the factors were lower Zokinvy (lonafarnib) sales and the delayed receipt of EmendoBio's license revenue.
アンジェス revised its consolidated results forecast for the 2026 fiscal year ending December downward to revenue of ¥1.0 billion. Revenue is expected to decline from the previous period, but operating profit/loss, ordinary profit/loss and net income attributable to owners of the parent are each expected to improve, with the losses narrowing.
Revenue is expected to decrease by ¥330 million. Operating loss is expected to be ¥8.9 billion, ordinary loss ¥9.0 billion and net loss ¥9.1 billion, with the respective changes in amount indicated. The main factors are that Zokinvy (lonafarnib) sales are expected to fall below the initial forecast and that receipt of EmendoBio's license revenue has shifted to the next fiscal year.
Zokinvy (lonafarnib) sales totaled ¥328 million for the cumulative March to September 2026 period, accounting for approximately 43.7% of business revenue of ¥751 million. This is affecting the overall revenue mix.
To expand Zokinvy (lonafarnib) sales, the company has been jointly advancing the search for new indications with AI drug discovery company OptimAIze since December 2025. Meanwhile, losses are expected to decrease because part of the cost of manufacturing the active pharmaceutical ingredient for the HGF gene therapy product Collategene is expected to be recognised next fiscal year.